School of Medicine


Showing 1-10 of 82 Results

  • Saurabh Dahiya, MD, FACP

    Saurabh Dahiya, MD, FACP

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Dahiya is a cancer specialist with board certification in internal medicine, hematology, and medical oncology. He is an Associate Professor at Stanford University School of Medicine and Clinical Director of Cancer Cell Therapy in the Stanford BMT and Cell Therapy division.

    Dr. Dahiya strives to support each patient with a personalized and compassionate care plan that optimizes healing and quality of life.

    Prior to joining Stanford, Dr. Dahiya was an associate professor of medicine at the Greenebaum Comprehensive Cancer Center at the University of Maryland School of Medicine, where he developed the Cellular Immunotherapy Program and served as the Director of Cellular Immunotherapy in leukemia and lymphoma.

    Dr. Dahiya’s research focuses on cellular immunotherapy for hematologic malignancies. He has led and participated in several investigator-initiated studies and sponsored clinical trials with cell therapies (CAR-T, CAR-NK, TCR-T) for hematologic malignancies. His research group is also involved in various translational research activities for the standard of care and research CAR-T therapy. Dr. Dahiya’s group was the first group to show the role of fibrinogen in Neurotoxicity associated with CAR-T therapy. They showed vascular injury as manifested by high fibrinogen levels is associated with higher Neurotoxicity in patients who receive CAR-T therapy. More recently his group led a novel study of assessing the immune response to COVID-19 disease. They evaluated the immune response in critically ill and non-critically ill patients hospitalized with COVID-19 disease and showed a differential immune response between the groups. Dr. Dahiya’s group also showed and established poor immunogenicity of COVID-19 vaccines in CART recipients. As such, passive immunity and other strategies to address the issues of immunogenicity are being explored.

    He has published more than 50 articles in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, Blood, Blood Advances, Lancet, Leukemia Research, Neuro-Oncology, and many more. He reviews article submissions for the journals Critical Reviews in Oncology and Hematology, Thoracic Cancer, and Blood. He serves as the hematology lead editor for the journal Critical Reviews in Oncology and Hematology.

    He has presented his research findings at conferences such as the annual meetings of the American Society of Hematology, American Society of Clinical Oncology, and American Society for Transplantation and Cell Therapy.

    Dr. Dahiya is a member of the American Society of Hematology and the American Society of Transplantation and Cell Therapy.

  • Sudeb C. Dalai

    Sudeb C. Dalai

    Adjunct Clinical Assistant Professor, Medicine - Infectious Diseases

    BioDr. Sudeb Dalai, MD PhD is an Infectious Disease Physician at Stanford University School of Medicine and the Palo Alto Medical Foundation. Currently a Clinical Assistant Professor (Teaching) at Stanford, he has taught courses and conducted research in academia/industry for over 18 years.

    Dr. Dalai completed his undergraduate degree at MIT, MD and MS at Stanford, PhD in Epidemiology at UC Berkeley School of Public Health, Internal Medicine Residency at UCSD, and Fellowship in Infectious Diseases at Stanford. He has received numerous teaching and leadership awards and research grants and has co-authored multiple peer-reviewed publications. His work has been supported by the Infectious Diseases Society of America, the Howard Hughes Medical Institute, the Paul and Daisy Soros Foundation, and the National Institutes of Health. Dr. Dalai is an internationally-invited speaker and has been featured in multiple media outlets including ABC, NBC, Good Morning America, US News & World Report, Buzzfeed, and The Huffington Post. In 2003 he was elected to the MIT Board of Trustees and in 2020 he was voted as a Board Member of the MIT Club of Northern California.

  • Daniel Fridljand

    Daniel Fridljand

    Affiliate, Primary Care and Population Health

    BioVisiting student researcher

    Education:
    Oct 2017 - May 2023: Univ. of Heidelberg, M.Sc. (Mathematics)